Skip to main content

Day: March 12, 2021

BTCS Interview to Air on Bloomberg TV in the US on the RedChip Money Report®

Silver Spring, MD, March 12, 2021 (GLOBE NEWSWIRE) — BTCS Inc. (OTCQB: BTCS) (“BTCS” or the “Company”), a digital asset and blockchain technology focused company, today announced an interview with Charles Allen, Chief Executive Officer, will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, March 13, at 7 p.m. local time in 73M homes across the United States. The RedChip Money Report® also airs on Bloomberg International in Europe in 100M homes at 6 pm local time on Sundays.In the exclusive interview, Allen discusses the launch of the Company’s revenue-generating staking operation on ethereum 2.0, pioneering digital asset treasury strategy, and development of a proprietary digital analytics platform.To view the interview segment, please visit: https://youtu.be/6LBxvg00p5g“The RedChip Money Report” delivers...

Continue reading

Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021

LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Friday, March 19, 2021 to discuss financial results for the year ended December 31, 2020 and provide an update on clinical development programs with GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin under investigator-sponsored development for several cancer indications. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines. The Company’s immunotherapy candidate,...

Continue reading

Bonanza Creek Energy, Inc. and HighPoint Resources Announce Final Results of Exchange Offer and Consent Solicitations

DENVER, March 12, 2021 (GLOBE NEWSWIRE) — Bonanza Creek Energy, Inc. (NYSE: BCEI) (the “Company” or “Bonanza Creek”) and HighPoint Resources Corporation (“HighPoint”) (NYSE: HPR) today announced the expiration and results of Bonanza Creek’s previously announced offer to exchange (the “Exchange Offer”) shares of its common stock and newly issued 7.5% Senior Notes due 2026 (the “Bonanza Creek Senior Notes”) for any and all of the 7.0% Senior Notes due October 15, 2022 (the “2022 Notes”) of HighPoint Operating Corporation (“HighPoint OpCo”) and the 8.75% Senior Notes due June 15, 2025 of HighPoint OpCo (the “2025 Notes” and, together with the 2022 Notes, the “HighPoint Senior Notes”) as of 5:00 p.m. New York City time on March 11, 2021 (the “Expiration Deadline”). The Exchange Offers were commenced in connection with Bonanza Creek’s...

Continue reading

Discovery Announces Appointment of Jennifer Wagner to Board

TORONTO, March 12, 2021 (GLOBE NEWSWIRE) — Discovery Metals Corp. (TSX-V: DSV, OTCQX: DSVMF) (“Discovery” or the “Company”) is pleased to announce the appointment of Jennifer Wagner to the Company’s Board of Directors (the “Board”).Ms. Wagner is a corporate securities lawyer with 15 years of experience in the mining sector. She is currently Executive Vice-President, Corporate Affairs and Sustainability at Kirkland Lake Gold Ltd. (“Kirkland Lake”). Prior to joining Kirkland Lake in 2015, she acted as legal counsel and corporate secretary to various TSX and TSXV listed mining companies. Ms. Wagner has extensive experience advising companies on a variety of corporate commercial transactions, governance, and compliance matters. Ms. Wagner received a Bachelor of Arts from McGill University and an LL.B. from the University of Windsor.Murray...

Continue reading

Brain Scientific Featured in Syndicated Broadcast Covering Receipt of FDA Clearance for Next-Gen NeuroCap EEG Headset

NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Brain Scientific Inc. (OTCQB: BRSF ) today announces it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers Brain Scientific’s receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired.To hear the audio production, visit: https://nnw.fm/um28XTo read the original press release, visit: https://nnw.fm/TgVmq“We are constantly working on new products...

Continue reading

Shared Spectrum Company and InterDigital, Inc. Selected to lead DoD 5G Spectrum Sharing-Application Award

VIENNA, Va., March 12, 2021 (GLOBE NEWSWIRE) — Shared Spectrum Company (a leading innovator of spectrum intelligence software and solutions), and InterDigital, Inc., (a mobile and video technology research and development company) were awarded a contract to develop technologies to advance 5G-enabled dynamic spectrum sharing. This project enables dynamic spectrum sharing between Air Force radars and 5G cellular services at Hill Air Force Base, Utah in the 3.1 – 3.45 GHz band. This project delivers 5G network enhancements to address spectrum coexistence and security solutions through existing APIs and through modification of 5G protocols, implements the techniques on a prototype hardware, performs trade studies to improve and investigate other techniques, and to mature, integrate and deploy at scale into the 5G testbed.“Dynamic spectrum...

Continue reading

Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public offering of 1,807,143 shares of its common stock, offered at a price of $7.00 to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 271,071 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being offered by the Company. The offering is expected to close on or about March 16, 2021, subject to customary closing conditions. The gross proceeds to the Company from this offering...

Continue reading

FuelCell Energy Announces Joining Hydrogen Europe

DANBURY, Conn., March 12, 2021 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) — a global leader in fuel cell technology—with a purpose of utilizing its proprietary, state-of-the-art fuel cell platforms to enable a world empowered by clean energy—today announced it has joined Hydrogen Europe, the leading European association representing the interests of the hydrogen and fuel cell industry and its stakeholders. FuelCell Energy, by joining Hydrogen Europe, joins a community of major companies working to significantly advance and accelerate the hydrogen economy.“We, at FuelCell Energy, have set our sights on becoming a leading global player in the distributed hydrogen production market,” said Mr. Jason Few, President and CEO. “FuelCell Energy brings its over 50 years of experience of developing, commercializing, manufacturing...

Continue reading

Claritas Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107

SAN FRANCISCO and TORONTO, March 12, 2021 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has completed GLP toxicology studies of R-107 in rodents. Claritas is developing R-107 as a therapy for vaccine-resistant COVID-19, influenza, and other viral diseases.The rodent toxicology studies were completed at Covance Laboratories, Inc., under full Good Laboratory Practice (GLP) compliance, which is a prerequisite to Phase 1 clinical studies according to FDA guidelines. Covance was named the “Global Contract Research Organization (CRO) Company of the Year” in 2020 by Frost & Sullivan and is considered to be the world’s premier comprehensive drug development company, dedicated to...

Continue reading

Elanders strengthens its offer within sustainable services with the acquisition of ReuseIT

Today, Elanders signed a contract to acquire 70 per cent of the shares in ReuseIT Sweden AB and ReuseIT Finance AB (”ReuseIT”). ReuseIT is a fast-growing company that in 2020 had net sales of nearly MSEK 70 with good profitability. They specialize in purchasing, securely wiping, refurbishing, selling and leasing used IT products. The acquisition makes Elanders a leading actor on the Swedish market. At the same time, it is part of a bigger strategic effort concerning sustainable services on a global level.With the acquisition of ReuseIT and the previous acquisition of Azalea Global IT AB, Elanders offers new and existing customers one of the market’s strongest offers within Renewed Tech. For customers this means that IT equipment destined to be discarded can instead be securely wiped, restored and sold by Elanders. This prevents corporate...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.